Significant response to apatinib monotherapy in heavily pretreated advanced HER2-positive breast cancer: a case report and literature review

References

• Althuis MD, Dozier JM, Anderson WF, Devesa SS, Brinton LA. Global trends in breast cancer incidence and mortality 1973–1997. Int J Epidemiol. 2005;34:405–412. doi:10.1093/ije/dyh414.
   PubMed Web of Science ®Google Scholar
• Loibl S, Gianni L. HER2-positive breast cancer. Lancet. 2017;389:2415–2429. doi:10.1016/S0140-6736(16)32417-5.
   PubMed Web of Science ®Google Scholar
• Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, Castro G Jr., Untch M, Smith I, Gianni L, et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017;389:1195–1205. doi:10.1016/S0140-6736(16)32616-2.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–792. doi:10.1056/NEJM200103153441101.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674. doi:10.1016/j.cell.2011.02.013.
   PubMed Web of Science ®Google Scholar
• Banerjee S, Dowsett M, Ashworth A, Martin LA. Mechanisms of disease: angiogenesis and the management of breast cancer. Nat Clin Pract Oncol. 2007;4:536–550. doi:10.1038/ncponc0905.
   PubMedGoogle Scholar
• Schirosi L, De Summa S, Tommasi S, Paradiso A, Gasparini G, Popescu O, Simone G, Mangia A. VEGF and TWIST1 in a 16-biomarker immunoprofile useful for prognosis of breast cancer patients. Int J Cancer. 2017;141:1901–1911. doi:10.1002/ijc.30868.
   PubMed Web of Science ®Google Scholar
• Sitohy B, Nagy JA, Dvorak HF. Anti-VEGF/VEGFR therapy for cancer: reassessing the target. Cancer Res. 2012;72:1909–1914. doi:10.1158/0008-5472.CAN-11-3406.
   PubMed Web of Science ®Google Scholar
• Miles DW, Chan A, Dirix LY, Cortes J, Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010;28:3239–3247. doi:10.1200/JCO.2008.21.6457.
   PubMed Web of Science ®Google Scholar
• Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666–2676. doi:10.1056/NEJMoa072113.
   PubMed Web of Science ®Google Scholar
• Robert NJ, Dieras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SY, Zhou X, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011;29:1252–1260. doi:10.1200/JCO.2010.28.0982.
   PubMed Web of Science ®Google Scholar
• Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O’Neill V, Rugo HS. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2011;29:4286–4293. doi:10.1200/JCO.2010.34.1255.
   PubMed Web of Science ®Google Scholar
• Vahdat LT, Layman R, Yardley DA, Gradishar W, Salkeni MA, Joy AA, Garcia AA, Ward P, Khatcheressian J, Sparano J, et al. Randomized Phase II study of ramucirumab or icrucumab in combination with capecitabine in patients with previously treated locally advanced or metastatic breast cancer. Oncologist. 2017;22:245–254. doi:10.1634/theoncologist.2016-0265.
   PubMed Web of Science ®Google Scholar
• Yardley DA, Reeves J, Dees EC, Osborne C, Paul D, Ademuyiwa F, Soliman H, Guthrie T, Andersen J, Krekow L, et al. Ramucirumab with eribulin versus eribulin in locally recurrent or metastatic breast cancer previously treated with anthracycline and taxane therapy: a multicenter, randomized, Phase II study. Clin Breast Cancer. 2016;16:471–9 e1. doi:10.1016/j.clbc.2016.07.005.
   PubMed Web of Science ®Google Scholar
• Mackey JR, Ramos-Vazquez M, Lipatov O, McCarthy N, Krasnozhon D, Semiglazov V, Manikhas A, Gelmon KA, Konecny GE, Webster M, et al. Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer. J Clin Oncol. 2015;33:141–148. doi:10.1200/JCO.2014.57.1513.
   PubMed Web of Science ®Google Scholar
• Spera G, Fresco R, Fung H, Dyck JRB, Pituskin E, Paterson I, Mackey JR. Beta blockers and improved progression-free survival in patients with advanced HER2 negative breast cancer: a retrospective analysis of the ROSE/TRIO-012 study. Ann Oncol. 2017;28:1836–1841. doi:10.1093/annonc/mdx264.
   PubMed Web of Science ®Google Scholar
• Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9:327–337.
   PubMed Web of Science ®Google Scholar
• Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, Simantov R, Kelley S. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 2006;5:835–844. doi:10.1038/nrd2130.
   PubMed Web of Science ®Google Scholar
• Bianchi G, Loibl S, Zamagni C, Salvagni S, Raab G, Siena S, Laferriere N, Pena C, Lathia C, Bergamini L, et al. Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. Anticancer Drugs. 2009;20:616–624. doi:10.1097/CAD.0b013e32832b2ea0.
   PubMed Web of Science ®Google Scholar
• Moreno-Aspitia A, Morton RF, Hillman DW, Lingle WL, Rowland KM Jr., Wiesenfeld M, Flynn PJ, Fitch TR, Perez EA. Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. J Clin Oncol. 2009;27:11–15. doi:10.1200/JCO.2007.15.5242.
   PubMed Web of Science ®Google Scholar
• Li J, Zhao X, Chen L, Guo H, Lv F, Jia K, Yv K, Wang F, Li C, Qian J, et al. Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies. BMC Cancer. 2010;10:529. doi:10.1186/1471-2407-10-529.
   PubMed Web of Science ®Google Scholar
• Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, Liu W, Tong J, Liu Y, Xu R, et al. Randomized, double-blind, placebo-controlled Phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol. 2016;34:1448–1454. doi:10.1200/JCO.2015.63.5995.
   PubMed Web of Science ®Google Scholar
• Hu X, Cao J, Hu W, Wu C, Pan Y, Cai L, Tong Z, Wang S, Li J, Wang Z, et al. Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer. BMC Cancer. 2014;14:820. doi:10.1186/1471-2407-14-820.
   PubMed Web of Science ®Google Scholar
• Hu X, Zhang J, Xu B, Jiang Z, Ragaz J, Tong Z, Zhang Q, Wang X, Feng J, Pang D, et al. Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer. Int J Cancer. 2014;135:1961–1969. doi:10.1002/ijc.28829.
   PubMed Web of Science ®Google Scholar
• Hirotsu Y, Nakagomi H, Amemiya K, Oyama T, Inoue M, Mochizuki H, Omata M. Intrinsic HER2 V777L mutation mediates resistance to trastuzumab in a breast cancer patient. Med Oncol. 2017;34:3. doi:10.1007/s12032-016-0857-2.
   PubMed Web of Science ®Google Scholar
• Tortora G. Mechanisms of resistance to HER2 target therapy. J Natl Cancer Inst Monogr. 2011;2011:95–98. doi:10.1093/jncimonographs/lgr026.
   PubMedGoogle Scholar
• Herter-Sprie GS, Greulich H, Wong KK. Activating mutations in ERBB2 and their impact on diagnostics and treatment. Front Oncol. 2013;3:86. doi:10.3389/fonc.2013.00086.
   PubMedGoogle Scholar
• Alameddine RS, Otrock ZK, Awada A, Shamseddine A. Crosstalk between HER2 signaling and angiogenesis in breast cancer: molecular basis, clinical applications and challenges. Curr Opin Oncol. 2013;25:313–324. doi:10.1097/CCO.0b013e32835ff362.
   PubMed Web of Science ®Google Scholar
• Nasir A, Holzer TR, Chen M, Man MZ, Schade AE. Differential expression of VEGFR2 protein in HER2 positive primary human breast cancer: potential relevance to anti-angiogenic therapies. Cancer Cell Int. 2017;17:56. doi:10.1186/s12935-017-0427-5.
   PubMed Web of Science ®Google Scholar
• Rugo HS, Chien AJ, Franco SX, Stopeck AT, Glencer A, Lahiri S, Arbushites MC, Scott J, Park JW, Hudis C, et al. A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat. 2012;134:13–20. doi:10.1007/s10549-011-1918-z.
   PubMed Web of Science ®Google Scholar
• Schwartzberg LS, Badarinath S, Keaton MR, Childs BH. Phase II multicenter study of docetaxel and bevacizumab with or without trastuzumab as first-line treatment for patients with metastatic breast cancer. Clin Breast Cancer. 2014;14:161–168. doi:10.1016/j.clbc.2013.12.003.
   PubMed Web of Science ®Google Scholar
• Lin NU, Seah DS, Gelman R, Desantis S, Mayer EL, Isakoff S, Dipiro P, Krop IE, Come SE, Weckstein D, et al. A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2013;139:403–410. doi:10.1007/s10549-013-2551-9.
   PubMed Web of Science ®Google Scholar
• Martin M, Makhson A, Gligorov J, Lichinitser M, Lluch A, Semiglazov V, Scotto N, Mitchell L, Tjulandin S. Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer. Oncologist. 2012;17:469–475. doi:10.1634/theoncologist.2011-0344.
   PubMed Web of Science ®Google Scholar
• Gianni L, Romieu GH, Lichinitser M, Serrano SV, Mansutti M, Pivot X, Mariani P, Andre F, Chan A, Lipatov O, et al. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. J Clin Oncol. 2013;31:1719–1725. doi:10.1200/JCO.2012.44.7912.
   PubMed Web of Science ®Google Scholar
• Bergh J, Bondarenko IM, Lichinitser MR, Liljegren A, Greil R, Voytko NL, Makhson AN, Cortes J, Lortholary A, Bischoff J, et al. First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. J Clin Oncol. 2012;30:921–929. doi:10.1200/JCO.2011.35.7376.
   PubMed Web of Science ®Google Scholar
• Baselga J, Segalla JG, Roche H, Del Giglio A, Pinczowski H, Ciruelos EM, Filho SC, Gomez P, Van Eyll B, Bermejo B, et al. Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer. J Clin Oncol. 2012;30:1484–1491. doi:10.1200/JCO.2011.36.7771.
   PubMed Web of Science ®Google Scholar
• Tian S, Quan H, Xie C, Guo H, Lu F, Xu Y, Li J, Lou L. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci. 2011;102:1374–1380. doi:10.1111/j.1349-7006.2011.01939.x.
   PubMed Web of Science ®Google Scholar
• Fan M, Zhang J, Wang Z, Wang B, Zhang Q, Zheng C, Li T, Ni C, Wu Z, Shao Z, et al. Phosphorylated VEGFR2 and hypertension: potential biomarkers to indicate VEGF-dependency of advanced breast cancer in anti-angiogenic therapy. Breast Cancer Res Treat. 2014;143:141–151. doi:10.1007/s10549-013-2793-6.
   PubMed Web of Science ®Google Scholar
• Holmes K, Roberts OL, Thomas AM, Cross MJ. Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal. 2007;19:2003–2012. doi:10.1016/j.cellsig.2007.05.013.
   PubMed Web of Science ®Google Scholar
• Casella I, Feccia T, Chelucci C, Samoggia P, Castelli G, Guerriero R, Parolini I, Petrucci E, Pelosi E, Morsilli O, et al. Autocrine-paracrine VEGF loops potentiate the maturation of megakaryocytic precursors through Flt1 receptor. Blood. 2003;101:1316–1323. doi:10.1182/blood-2002-07-2184.
   PubMed Web of Science ®Google Scholar
• Liang Y, Brekken RA, Hyder SM. Vascular endothelial growth factor induces proliferation of breast cancer cells and inhibits the anti-proliferative activity of anti-hormones. Endocr Relat Cancer. 2006;13:905–919. doi:10.1677/erc.1.01221.
   PubMed Web of Science ®Google Scholar
• Weigand M, Hantel P, Kreienberg R, Waltenberger J. Autocrine vascular endothelial growth factor signalling in breast cancer. Evidence from cell lines and primary breast cancer cultures in vitro. Angiogenesis. 2005;8:197–204. doi:10.1007/s10456-005-9010-0.
   PubMedGoogle Scholar
• Pfister NT, Fomin V, Regunath K, Zhou JY, Zhou W, Silwal-Pandit L, Freed-Pastor WA, Laptenko O, Neo SP, Bargonetti J, et al. Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells. Genes Dev. 2015;29:1298–1315. doi:10.1101/gad.263202.115.
   PubMed Web of Science ®Google Scholar